538 related articles for article (PubMed ID: 25354827)
1. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
[TBL] [Abstract][Full Text] [Related]
2. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
[TBL] [Abstract][Full Text] [Related]
3. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
van den Bos W; de Bruin DM; van Randen A; Engelbrecht MR; Postema AW; Muller BG; Varkarakis IM; Skolarikos A; Savci-Heijink CD; Jurhill RR; Zondervan PJ; Laguna Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
Eur Radiol; 2016 Jul; 26(7):2252-60. PubMed ID: 26449559
[TBL] [Abstract][Full Text] [Related]
4. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
[TBL] [Abstract][Full Text] [Related]
5. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients.
van den Bos W; de Bruin DM; Jurhill RR; Savci-Heijink CD; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna-Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
World J Urol; 2016 May; 34(5):657-64. PubMed ID: 26296371
[TBL] [Abstract][Full Text] [Related]
6. Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study.
van den Bos W; Jurhill RR; de Bruin DM; Savci-Heijink CD; Postema AW; Wagstaff PG; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna Pes MP; de Reijke TM; de la Rosette JJ
J Urol; 2016 Aug; 196(2):552-9. PubMed ID: 27004693
[TBL] [Abstract][Full Text] [Related]
7. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of irreversible electroporation for the ablation of renal masses: a prospective, human, in-vivo study protocol.
Wagstaff PG; de Bruin DM; Zondervan PJ; Savci Heijink CD; Engelbrecht MR; van Delden OM; van Leeuwen TG; Wijkstra H; de la Rosette JJ; Laguna Pes MP
BMC Cancer; 2015 Mar; 15():165. PubMed ID: 25886058
[TBL] [Abstract][Full Text] [Related]
9. Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.
Scheltema MJ; Postema AW; de Bruin DM; Buijs M; Engelbrecht MR; Laguna MP; Wijkstra H; de Reijke TM; de la Rosette JJMCH
Diagn Interv Radiol; 2017; 23(5):365-370. PubMed ID: 28830850
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up.
Beyer LP; Pregler B; Nießen C; Michalik K; Haimerl M; Stroszczynski C; Jung EM; Wiggermann P
Clin Hemorheol Microcirc; 2016; 64(3):501-506. PubMed ID: 27935553
[TBL] [Abstract][Full Text] [Related]
11. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
Blazevski A; Amin A; Scheltema MJ; Balakrishnan A; Haynes AM; Barreto D; Cusick T; Thompson J; Stricker PD
World J Urol; 2021 Apr; 39(4):1107-1114. PubMed ID: 32488359
[TBL] [Abstract][Full Text] [Related]
12. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J
JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911
[TBL] [Abstract][Full Text] [Related]
13. First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial.
Wendler JJ; Ricke J; Pech M; Fischbach F; Jürgens J; Siedentopf S; Roessner A; Porsch M; Baumunk D; Schostak M; Köllermann J; Liehr UB
Cardiovasc Intervent Radiol; 2016 Feb; 39(2):239-50. PubMed ID: 26341653
[TBL] [Abstract][Full Text] [Related]
14. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
Blazevski A; Scheltema MJ; Amin A; Thompson JE; Lawrentschuk N; Stricker PD
BJU Int; 2020 Mar; 125(3):369-378. PubMed ID: 31725935
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.
Guenther E; Klein N; Zapf S; Weil S; Schlosser C; Rubinsky B; Stehling MK
PLoS One; 2019; 14(4):e0215093. PubMed ID: 30986263
[TBL] [Abstract][Full Text] [Related]
16. Irreversible Electroporation for the Ablation of Prostate Cancer.
Karagiannis A; Varkarakis J
Curr Urol Rep; 2019 Sep; 20(10):63. PubMed ID: 31478109
[TBL] [Abstract][Full Text] [Related]
17. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
[TBL] [Abstract][Full Text] [Related]
18. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.
Scheltema MJ; Chang JI; Böhm M; van den Bos W; Blazevski A; Gielchinsky I; Kalsbeek AMF; van Leeuwen PJ; Nguyen TV; de Reijke TM; Siriwardana AR; Thompson JE; de la Rosette JJ; Stricker PD
World J Urol; 2018 Sep; 36(9):1383-1389. PubMed ID: 29594551
[TBL] [Abstract][Full Text] [Related]
19. Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study).
Wendler JJ; Pech M; Fischbach F; Jürgens J; Friebe B; Baumunk D; Porsch M; Blaschke S; Schindele D; Siedentopf S; Ricke J; Schostak M; Köllermann J; Liehr UB
Urology; 2018 Apr; 114():224-232. PubMed ID: 29305201
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
